Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconst… (NCT07135687) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction
United States144 participantsStarted 2026-08
Plain-language summary
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Must be undergoing a primary ACLR with or without the following:
* Chondroplasty
* Synovectomy
* Loose body removal
* Removal of hardware
* Meniscal surgery (excluding meniscal allograft transplantation/MAT)
* Lateral extra-articular tenodesis
* Must have skeletal maturity in the distal femur and proximal tibial physes
* Must be age 18 years or older at time of enrollment
Exclusion Criteria:
* \<18 years at time of enrollment
* No diagnosis of ACL tear
* ACL repairs
* Revision ACL reconstructions
* Open distal femur or proximal tibia physes
* Major concomitant procedures (such as osteotomy, MAT, or cartilage restoration surgery)
* History of prior proximal or distal femur fracture (including those receiving nonoperative treatment)
* History of prior ipsilateral femur or tibia osteomyelitis
* Medical history
* History of hypotensive disease, including postural orthostatic hypotension syndrome (POTS), autonomic dysreflexia, or Shy-Drager syndrome (aka multiple system atrophy), baseline hypotension \<90 systolic or \<60 diastolic mmHg.
* History of significant hepatic disease (liver transplantation, cirrhosis of any cause, or any liver disease with Child-Pugh classification B or C) due to hepatic metabolism of ARBs.
* Chronic kidney disease
* Rheumatologic disorders on immunologic medications
* Current medications including diuretics (i.e. furosemide), lithium, and spironolactone
* Current hypertension with prescription of an ARB or ACE-I
* Allergy to lo…